INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.
Key stats and ratios
|
| Net profit margin | 24.16% | -157.52% |
| Operating margin | 27.56% | -151.46% |
| EBITD margin | - | -105.81% |
| Return on average assets | 51.37% | -122.81% |
| Return on average equity | - | - |
| Employees | 119 | - |
| Carbon Disclosure Rating | - | - |
Address
444 South Ellis Street
CHANDLER, AZ 85224
United States
No comments:
Post a Comment